Four RCTs compared the efficacy and safety between ICIs and chemotherapy, including 1310 patients with high PD‐L1 expression defined as tumor proportion score (TPS) ≥50%, who were treated with pembrolizumab, or with high TMB defined as TMB ≥ 10 mutation/megabase (mut/Mb) or TMB ≥ 243 mutations in whole exome sequencing, who were treated with nivolumab monotherapy or combined with ipilimumab. The gene discussed is CD274; the disease is neoplasm.